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Abstract
The human P2Y1 receptor was expressed in the yeast Saccharomyces cerevisiae strain MPY578q5, which is engineered to
couple to mammalian G protein-coupled receptors (GPCRs) and requires agonist-induced activation for growth. A range
of known P2Y1 receptor agonists were examined with the yeast growth assay system, and the results were validated by
comparing with potencies in the transfected 1321N1 astrocytoma cell line, in which calcium mobilization was measured
with a FLIPR (ﬂuorometric-imaging plate reader). The data were also compared with those from phospholipase C
activation and radioligand binding with the use of a newly available radioligand [
3H]MRS2279 (2-chloro-N
6-methyl-(N)-
methanocarba-20-deoxyadenosine-30,50-bisphosphate). In the yeast growth assay, the rank order of potency of 2-MeSADP
(2-methylthioadenosine 50-diphosphate), ADP (adenosine 50-diphosphate), and ATP (adenosine 50-triphosphate) is the
same as those in other assay systems, i.e., 2-MeSADP9ADP9ATP. The P2Y1-selective antagonist MRS2179 (N
6-methyl-
2-deoxyadenosine-30,50-bisphosphate) was shown to act as an antagonist with similar potency in all systems. The results
suggest that the yeast expression system is suitable for screening P2Y1 receptor ligands, both agonists and antagonists.
The yeast system should be useful for random mutagenesis of GPCRs to identify mutants with certain properties, such as
selective potency enhancement for small synthetic molecules and constitutive activity.
Abbreviations: 2-MeSADP– 2-methylthioadenosine 50-diphosphate; 3AM-ATP–30-amino-30-deoxy-ATP; 3-AT–3-amino-
1,2,4-triazole; ADP–adenosine 50-diphosphate; ADP-b-S–adenosine 50-O-(2-thio-diphosphate); ATP–adenosine 50-
triphosphate; FLIPR–ﬂuorometric-imaging plate reader; GAPDH–glyceraldehyde-3-phosphate dehydrogenase; GPCR–G
protein-coupled receptor; HT-AMP–2-hexylthioadenosine 50-monophosphate; IP3–inositol trisphosphate; MRS2179–N
6-
methyl-20-deoxyadenosine-30,5 0- bisphosphate; MRS2279– 2-chloro-N
6-methyl-(N)-methanocarba-20-deoxyadenosine-30,
50-bisphosphate; PAPET-ATP–2-[4-amino(2-phenylethyl)thio]-ATP; PBS–phosphate-buffered saline; PLC–phospholipase
C; SC–synthetic complete; SC-URA–SC media lacking uracil; SC-URAYHIS–SC media lacking uracil and histidine;
UDP– uridine 50-diphosphate; UTP– uridine 50-triphosphate
Introduction
Extracellular purines are important signaling molecules
responsible for biological effects mediated by cell surface
receptors [1Y3]. The family of purine receptors includes
adenosine (P1 receptors) and P2 receptors. The P2 class,
which primarily recognizes ATP (adenosine 50-triphos-
phate) and ADP (adenosine 50-diphosphate), has been
subdivided into subfamilies of P2X ligand-gated ion
channels and P2Y seven-transmembrane-spanning G pro-
tein-coupled receptors (GPCRs).
The P2Y1 receptor couples preferentially to Gq, which
activates phospholipase Cb(PLC), leading to formation of
inositol triphosphate (IP3) and mobilization of intracellular
Ca
2+. Various assays are available to measure the down-
stream signaling, with measurement of PLC being a
common, classical technique [4]. Previous reports showed
that assay results may vary signiﬁcantly, depending on the
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set out to establish the yeast assay system and to compare
measurement at this level of the signaling cascade, which
is dependent on activation of the G protein, with other
subsequent levels, i.e., PLC and Ca
2+. The compounds tested
in this set of experiments included ADP, ATP, 2-MeSADP
(2-methylthioadenosine 50-diphosphate), ADP-b-S (adeno-
sine 50-O-(2-thio-diphosphate), HT-AMP (2-hexylthioade-
nosine 50-monophosphate), PAPET-ATP (2-[4-amino
(2-phenylethyl)thio]-ATP), and 3AM-ATP (30-amino-30-
deoxy-ATP) [7Y9]. The bisphosphate antagonist MRS2179
(N
6-methyl-20-deoxyadenosine-30,50-bisphosphate) [10],
which is highly selective for P2Y1 receptors, was also tested.
The yeast Saccharomyces cerevisiae was used to mea-
sure functional effects at the G protein level. This yeast
strain has a native signaling system to regulate mating [11].
Speciﬁcally, a GPCR (Ste2p) is activated by mating
pheromones, which bind to Ste2p, triggering a cascade of
events ultimately leading to up-regulation of mating-
speciﬁc genes and down-regulation of other pathways.
This particular system has been engineered to couple to
mammalian GPCRs [12Y16]. Several genetic modiﬁcations
were required for this purpose, including modiﬁcation of
the G protein a subunit, deletion of certain genes, and
insertion of reporter genes. Yeast assays for GPCRs have
grown in popularity, primarily because of the well-known
genetics of yeast, making manipulations straightforward,
and the ability to directly analyze a particular receptor in
the absence of other receptor subtypes. The speed of yeast
growth allows broad screening and use of random
mutagenesis of GPCRs to identify mutants with certain
properties, such as selective potency enhancement for
small synthetic molecules and constitutive activity [16, 17].
The results from the yeast system were compared to
pharmacological parameters reﬂecting later steps along the
signaling cascade, measured for the same compounds: acti-
vation of PLC and calcium mobilization. PLC results were
obtained from the 1321N1 astrocytoma cell line expressing
P2Y1 receptors as reported previously [18, 19], and cal-
cium levels were monitored in the same cell line. We set
out to explore the yeast system for P2Y receptors, not only
for conventional compound screening at the native recep-
tors, but also to develop genetically engineered receptors.
Because it is possible to introduce random mutagenesis and
to select for responsive clones [16, 17] by cell growth, yeast
promises to be a unique screening tool. One possible use is
identiﬁcation of mutant receptors (e.g., neoceptors) with
enhanced pharmacological properties [20].
Materials and methods
Materials
Yeast media components were purchased from Qbiogene,
Inc (Carlsbad, California, USA). The calcium assay kit was
from Molecular Devices (Sunnyvale, California, USA).
The compounds 3-amino-1,2,4-triazole (3-AT), probene-
cid, ADP, ATP, 3AM-ATP, 2-MeSADP, ADP-b-S, and
MRS2179 were from Sigma (St. Louis, Missouri, USA);
HT-AMP, PAPET-ATP, and [
3H]MRS2279 were synthe-
sized as previously reported [21Y23].
Yeast strain
The yeast Saccharomyces cerevisiae strain MPY578q5
(MATa GPA1 far1::LYS2 fus1::FUS1-HIS3 sst2::SST2-
G418
R ste2::LEU2 fus2::FUS2-CAN1 ura3 lys2 ade2 his3
leu2 trp1 can1) was used for expression experiments as
previously described [24, 17]. This strain contains a mutant
version of the GPA1 gene that codes for a Ga subunit in
which the last ﬁve amino acids are derived from the
mammalian aq (EYNLV). In addition, the deletion of
the FAR1 gene allows yeast to grow despite activation of
the pheromone pathway that normally leads to cell-cycle
arrest. The SST2 gene was disrupted to prevent attenuation
of G protein signaling mediated by the GTPase-activating
protein activity of Sst2p. The STE2 gene coding for the
yeast a factor receptor was deleted to prevent competition
for G proteins. The FUS1-HIS3 reporter makes the
production of the His3 protein dependent on receptor-
mediated activation of the yeast pheromone pathway.
Yeast expression plasmid
Expression plasmids used were based on p416GPD [24],
which is a single-copy plasmid containing the CEN/ARS
element, the URA3 gene as a selection marker in yeast, the
Amp gene for selection in Escherichia coli, and the yeast
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) pro-
moter. In particular, human P2Y1 was subcloned from
pCD-PS [25] into p416GPD to create p416-P2Y1, which
was conﬁrmed by DNA sequencing.
Yeast transformation and growth
Yeast cells were grown at 30 -C at 180 rpm in synthetic
complete (SC) media [26] unless otherwise noted. Yeast
transformations were performed with a lithium acetate
technique [27]. Transformants were selected and main-
tained in SC media lacking uracil (SC-URA).
Yeast liquid growth assay
Cells were grown overnight in 2-ml SC-URA. Cells were
then washed once with PBS and used at a working
concentration of õ50,000 cells/ml (based on the conver-
sion OD 0.1õ3 10
6 cells/ml) in SC media lacking uracil
and histidine (SC-URAYHIS) with 20-mM 3-AT. 3-AT is
an inhibitor of imidazole glycerol-phosphate dehydrase,
which decreases basal cell growth in histidine-deﬁcient
media because of leaky expression of FUS1-HIS3.A
quantity of 180 ml cells was added to each well of a ﬂat-
bottom 96-well plate. Then 20 ml of either compound at the
appropriate dilution or water (negative control) or histidine
242 R.T. Niebauer et al.stock (positive control) was added to each well. For
antagonist studies, 20 ml of both agonist and antagonist
was added to each well. Plates were incubated at room
temperature for several days. Immediately before measure-
ment, the contents of each well were pipette mixed, and the
optical density at 630 nm was measured with a plate
reader. Samples were run in triplicate and averaged.
Calcium mobilization assay
Human 1321N1 astrocytoma cells stably expressing human
P2Y1 receptors were cultured in Dulbecco’s modiﬁed
Eagle’s medium (JRH Biosciences, Inc., Lenexa, Kansas,
USA) and F12 (1:1) supplemented with 10% fetal bovine
serum, 100 units penicillin/ml, 100 mg streptomycin/ml, 2
mmol glutamine/ml, and 500 mg geneticin/ml. For the
assay, cells were grown overnight in 100 ml media in 96-
well ﬂat-bottom plates at 37 -Ca t5 %C O 2 or until they
reached õ60%Y80% conﬂuency. The calcium assay kit
(Molecular Devices) was used as directed with no washing
of cells and with probenecid added to the loading dye at a
ﬁnal concentration of 2.5 mM to increase dye retention.
Cells were loaded with 50-ml dye with probenecid in each
well and incubated for 45 min at room temperature. The
compound plate was prepared with dilutions of various
compounds in Hanks Buffer. For antagonist studies, both
agonist and antagonist were added to the sample plate.
Samples were run in duplicate with a Molecular Devices
Flexstation I at room temperature. Cell ﬂuorescence (excita-
tion = 485 nm; emission = 525 nm) was monitored following
exposure to compound. Increases in intracellular calcium are
reported as the maximum ﬂuorescence value after exposure
minus the basal ﬂuorescence value before exposure.
Binding assay
P2Y1 receptor binding experiments were performed as
previously described [23]. Brieﬂy, membranes (40 mg
protein) from astrocytoma cells stably expressing human
P2Y1 receptors were incubated with [
3H]MRS2279 (8 nM)
for 30 min at 4-C in a total assay volume of 200 ml. The
radiolabeled-ligand concentration used in the assay ap-
proximated the Kd value in binding to the receptor. Binding
reactions were terminated by ﬁltration through Whatman
GF/B glass-ﬁber ﬁlters under reduced pressure with a MT-
24 cell harvester (Brandel, Gaithersburg, Maryland), and
radioactivity was determined with a liquid scintillation
counter (Packard, Downers Grove, Illinois).
Statistical analysis
Binding and functional parameters were estimated with
GraphPad Prism software (GraphPad, San Diego, Califor-
nia, USA). Antagonist potency was evaluated by Schild
analysis [28]. The concentration ratio is equal to the EC50
of the agonist in the presence of the antagonist divided
by the EC50 of the agonist alone. KB is the Schild constant
of the antagonist. Data are expressed as mean T standard
error.
Results
Agonist effects on P2Y1 receptors in the yeast system
via growth assays
A yeast expression system was used for measurement of G
protein activation via P2Y1 receptors. To determine if the
human P2Y1 receptor could effectively couple to a G
protein, the haploid yeast (S. cerevisiae) strain MPY578q5
was used [17, 24]. The basic features of this strain include
numerous modiﬁcations to the native yeast pheromone
response pathway, including expression of a chimeric Gq
protein, such that it required productive receptor-G protein
coupling for growth in histidine-deﬁcient media. This yeast
strain harbors a mutant version of the GPA1 gene coding
for a hybrid yeast/mammalian G protein subunit in which
the last ﬁve amino acids of Gpa1p were replaced with the
corresponding residues present in mammalian aq [24]. This
strain was then transformed with the human P2Y1 gene in a
yeast expression plasmid. To determine conditions for
effective coupling, liquid growth assays were performed.
Care was taken to use 3-AT as shown previously to
suppress basal growth [16, 24]. To validate the effective-
ness of the system, we first tested two agonists, including
the endogenous P2Y1 receptor agonist ADP and the clas-
sical agonist 2-MeSADP. Basal growth was low in the
absence of any exogenously added nucleotides and in the
presence of UDP (data not shown), which was shown to be
relatively inactive at the P2Y1 receptor. The positive
control (addition of histidine to the media to check cell
viability) showed that the agonists examined were fully
efﬁcacious. These data showed that the chimeric G protein
was effectively coupled to the human P2Y1 receptor, which
was important to establish because many chimeras do not
effectively couple in yeast [29].
To compare present results with the available PLC data,
2-MeSADP, ADP, and ATP were studied. As shown in
Figure 1. Yeast growth assays in the presence of 2-MeSADP, ADP,
ATP. Representative data exhibiting the concentration-dependent growth
(represented as OD630) of the engineered yeast strain expressing P2Y1
receptors in the presence of 2-MeSADP, ADP, and ATP ranging in
concentration from 10
j10 to 10
j3 (M). The EC50 values averaged over at
least three experiments are 2-MeSADP (130 nM) 9 ADP (1800 nM) 9
ATP (28,000 nM). Experiments were performed at least three times with
representative data shown. Within each experiment each data point was
done in triplicate and averaged.
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similar to that of the published PLC data (Table 1).
To further test the yeast system, ADP-b-S, HT-AMP,
and two amine-derivatized agonists, PAPET-ATP and
3AM-ATP, were included. The amine-derivatized agonists
were demonstrated to be moderately potent in a PLC assay
or have moderate afﬁnity in binding [18, 19]. Because of
the charged amino group at the 30 position, 3AM-ATP has
possible future applications in helping to determine inter-
actions within the binding site at the molecular level (see
Discussion). The resulting EC50 values for all the com-
pounds are shown in Table 1. In general, the compounds
were equally potent in the yeast assay and in the PLC
assay.
Antagonist effects on P2Y1 receptors in the yeast system
via growth assays
To show that the results obtained were speciﬁc to P2Y1
receptors in the yeast system, the P2Y1-selective antagonist
MRS2179 was studied. The data obtained from the liquid
growth assay are shown in Figure 2. In this experiment the
agonist ADP was used as an activator of the P2Y1 receptor,
and MRS2179 antagonized the effects of ADP by causing a
right shift in the curve.
Agonist effects on P2Y1 receptors in astrocytoma cells
via calcium assays
We compared the agonist effects by using a different
second messenger, the increase in intracellular calcium
upon ligand exposure. These experiments were performed
on astrocytoma cells expressing the human P2Y1 receptor.
Upon addition of a nucleotide ligand, the calcium mobili-
zation was determined by the increase in ﬂuorescence in
response to a calcium-sensitive dye. In control experi-
ments, the absence of added nucleotides or the addition of
UDP or UTP did not induce any response. In addition,
astrocytoma cells (not expressing P2Y1 receptors) showed
no response to either ATP or ADP (data not shown). The
same set of compounds used in the yeast system was tested
in the astrocytoma system (Table 1). As was seen with the
yeast system and the PLC assays, the rank orders of 2-
MeSADP, ADP, and ATP as agonists were consistent. The
EC50 values for all the compounds are shown in Table 1. In
the calcium system, the EC50 values were consistently
lower than those in the PLC and binding assays and the
yeast assay. The rank orders of several of the known
compounds, 2-MeSADP, ADP, and ATP, were consistent
across the systems. However, ADP-b-S, HT-AMP, and
PAPET-ATP were more potent in the calcium measure-
ment than in other assays.
Antagonist effects on P2Y1 receptors in the astrocytoma
system
Intracellular calcium can be regulated by various stimuli;
therefore, to show consistency and speciﬁcity for the P2Y1
receptor, the antagonist MRS2179 (with ADP as an agonist)
Figure 2. Yeast growth assay in the presence of the antagonist
MRS2179. MRS2179 (N
6-methyl-2-deoxyadenosine-30,50-bisphosphate)
was used to antagonize ADP (adenosine 50-diphosphate) via a yeast
growth assay (represented as OD630). The MRS2179 concentration was
ﬁxed at either 0, 10
j6,1 0
j5,o r1 0
j4 (M) over an ADP range of 10
j10 to
10
j4 M. Increasing amounts of antagonist (10
j6,1 0
j5,1 0
j4 M) cause a
right shift in the curves. Each experimental data point was done in
triplicate and averaged.
Table 1. Potencies of adenine nucleotide derivatives measured in three functional assays of human P2Y1 receptors and in a receptor binding assay
a.
Functional potency (EC50, nM) Binding (Ki, nM)
Yeast growth PLC (astrocytoma) Calcium (astrocytoma) Astrocytoma
ADP 1800 T 650 660
a 58 T 17 900
a
2-MeSADP 130 T 43 36
a 1.7 T 0.2 57
a
ATP 28,000 T 18,000 2600
a 5400 T 3600 1200
a
ADP-b-S 21,000 T 9800 ND 86 T 42 710
HT-AMP 24,000 T 3900 1400
b 16 T 11 1700
PAPET-ATP 17,000 T 6500 ND 28 T 13 1100
3AM-ATP 9200 (n = 1) 10,000
c 3000 T 1500 ND
Unless noted, the following methods were used, as described in Materials and methods (n = 3, unless noted). The parameter measured in the engineered
yeast cells was growth, indicated by turbidity determinations. The activity designated PLC in 1321N1 astrocytoma cells stably expressing the human
P2Y1 receptor represents the accumulation of tritiated inositol phosphates isolated with ion exchange columns [4, 25]. Calcium transients in the same
cells were measured with a ﬂuorescent chelating dye method on a FlexStation in 96-well format. Ki values refer to competition for binding of
[
3H]MRS2279 [23].
ND Not determined.
aData from Gao et al. (2004) (astrocytoma cells) [19].
bData from Hoffmann et al. (1999) (COS-7 cells) [18].
cData from Moro et al. (1999) (COS-7 cells) [34].
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As shown in Figure 3B, Schild analysis provided a KB
value of 164 nM, which was comparable to the value of
KB=177 nM for MRS2179 previously reported [30].
Because this is a selective antagonist, it can be used as a
control to show that the previous calcium results were
speciﬁc and not artifacts of another receptor or pathway.
Because HT-AMP was much more potent in the calcium
assay than in the yeast assay, it was important to
demonstrate that HT-AMP acts as an agonist speciﬁcally
on P2Y1 receptors to induce calcium mobilization. To
conﬁrm this, the antagonist effects of MRS2179 were
tested with HT-AMP as the agonist (Figure 4A). Schild
analysis gave a KB value of 70 nM, which was similar to
that obtained with ADP as an agonist (Figure 4B).
Competition of agonists for the [
3H]MRS2279 binding to
membranes from astrocytoma cells stably expressing
human P2Y1 receptors
Because a clear discrepancy between the data for some
agonists in the yeast assay and in the calcium assay was
observed, we further examined the binding afﬁnity of these
compounds for the human P2Y1 receptor. HT-AMP, ADP-
b-S, and PAPET-ATP were shown to be much less potent
in the binding assay than in the calcium assay (Table 1).
The antagonist radioligand was used in the binding assay to
test the agonist potency, and the high- and low-afﬁnity
binding sites of these agonists have been analyzed.
Discussion
It was shown that the yeast system showed good signal-to-
noise ratios and low basal growth, suggesting that it can be
used in screening ligands for P2Y1 receptors. The data
from the yeast growth assays were generally consistent
with those from the previous assays of inositol phosphates
accumulation. The rank order for 2-MeSADP, ADP, and
ATP is consistent for the different techniques. All of the
compounds tested, including ATP, produced a maximal or
nearly maximal effect in the yeast growth assay. However,
we cannot conclude that ATP itself is a nearly full agonist
in this system, because cleavage of ATP to form the full
agonist ADP could not be ruled out. In all the systems, the
antagonist MRS2179 was able to right-shift the concen-
trationYresponse curve.
One application of the yeast growth assay involves the
neoceptor concept [20] for the P2Y1 receptors. Because P2
receptors are widespread in most tissues, many side effects
could potentially occur during therapeutic intervention. To
Figure 3. Effects of MRS2179 on ADP-induced calcium mobilization in
astrocytoma cells. (A) MRS2179 was used to antagonize the effects of the
agonist ADP in the calcium mobilization assay. The MRS2179 concen-
tration was ﬁxed at either 0, 5 10
j6,1 0
j6,1 0
j5,o r5  10
j4 (M) over an
ADP range of 10
j10 to 10
j5 (M). Increasing amounts of antagonist cause
a right shift in the curves. Each experimental data point was done in
duplicate and averaged. (B) A Schild analysis was performed to calculate
a KB of 164 nM.
Figure 4. Effects of MRS2179 on calcium mobilization induced by HT-
AMP in astrocytoma cells. (A) MRS2179 was used to antagonize the
effects of the agonist HT-AMP in the calcium mobilization assay. The
MRS2179 concentration was ﬁxed at either 0, 10
j6,5  10
j5,1 0
j5,o r
5 10
j4 (M) over an HT-AMP range of 10
j10 to 10
j4 (M). Increasing
amounts of antagonist cause a right shift in the curves. Each experimental
data point was done in duplicate and averaged. (B) A Schild analysis was
performed to calculate a KB of 70 nM.
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agonist design, and gene therapy has been proposed in
what is known as the neoceptor concept [20]. One of the
difﬁculties in this process is the identiﬁcation of potential
neoceptors, because site-directed mutagenesis can be labo-
rious. Insight gained from modeling approaches [30] helps
to predict potential mutagenesis sites, but this rational ap-
proach has met with only mild success. An alternative ap-
proach is to use the power of yeast genetics and screening
to create libraries of potential neoceptors and then screen
for possible candidates rapidly [31]. This technique was
used in the identiﬁcation of constitutively active mutant
receptors and in other applications [16, 17]. In this study,
3AM-ATP was studied as a potential neoligand because of
its charged nature caused by the amino group. Results
showed that 3AM-ATP was only mildly potent in either
the yeast or calcium measurements, thus leaving the pos-
sibility that the compound could potentially have enhanced
afﬁnity for a neoceptor via an electrostatic interaction.
A concern with the yeast assays is that the incubation
period occurred over several days, during which the com-
pound stability was questionable. For example, ATP could
be broken down to ADP and further to adenosine. Previous
work was performed with yeast systems and purinergic
ligands[32, 33]. Our data in yeast (EC50: 2-MeSADP = 130
nM, ADP = 1800 nM) compare well with those of previous
work [33] that used a yeast system (EC50: 2-MeSADP =
300 nM, ADP = 2300 nM), in which a different reporter
system was used, allowing for shorter incubation times (24
h). Furthermore, the potencies of these compounds in the
yeast system are similar to those from the assay of inositol
phosphates (Table 1). The agreement among these data
suggests that the longer incubation times in our studies did
not signiﬁcantly alter the results. The nature of the yeast
assay is such that the cells multiply numerous times,
requiring more agonist over time for continued growth.
When measurements were recorded at an earlier time
point, the same trends were observed, suggesting that
agonist effect was persistent in the medium over time. This
constancy in the effect may indicate that the agonist
species is largely unchanged over time, although the sta-
bility of the nucleotides has not been directly determined.
In general, both the yeast and calcium data were obtained
efﬁciently but should be analyzed with caution, as a clear
discrepancy in the potency of some agonists was observed.
The yeast system to measure G protein-level events may be
a unique measure of these events, because the traditional
GTPgS binding assay for G proteins has not been applied
successfully to the P2Y1 receptor. As a complement to
classical measurements (radioligand binding, PLC), these
assays can provide another measure of functionality
rapidly, and taken together the information could lead to
the best ways to screen and characterize novel ligands.
In summary, the human P2Y1 receptor was functionally
expressed in yeast, and for a variety of known agonists, the
rank order of potencies was similar to that found in other
assay systems. The results suggest that the yeast expression
system is suitable for screening P2Y1 receptor ligands, both
agonists and antagonists.
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